Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic
Abstract Beta interferons (IFN-β) are pleiotropic cytokines with antiviral properties. They play important roles in the pathogenesis of multiple sclerosis (MS), an incurable immune-mediated disorder of the central nervous system. The clinical expression of MS is heterogeneous, with relapses of neuro...
Gespeichert in:
Veröffentlicht in: | QJM : An International Journal of Medicine 2021-12, Vol.114 (10), p.691-697 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 697 |
---|---|
container_issue | 10 |
container_start_page | 691 |
container_title | QJM : An International Journal of Medicine |
container_volume | 114 |
creator | Dumitrescu, L Papathanasiou, A Coclitu, C Constantinescu, C S Popescu, B O Tanasescu, R |
description | Abstract
Beta interferons (IFN-β) are pleiotropic cytokines with antiviral properties. They play important roles in the pathogenesis of multiple sclerosis (MS), an incurable immune-mediated disorder of the central nervous system. The clinical expression of MS is heterogeneous, with relapses of neuroinflammation and with disability accrual in considerable part unrelated to the attacks. The injectable recombinant IFN-β preparations are the first approved disease-modifying treatments for MS. They have moderate efficacy in reducing the frequency of relapses, but good long-term cost-efficacy and safety profiles, so are still widely used. They have some tolerability and adherence issues, partly mitigated in recent years by the introduction of a PEGylated formulation and use of ‘smart’ autoinjector devices. Their general impact on long-term disability is modest but could be further improved by developing accurate tools for identifying the patient profile of best responders to IFN-β. Here, we present the IFN-β-based immunomodulatory therapeutic approaches in MS, highlighting their place in the current coronavirus disease (COVID-19) pandemic. The potential role of IFN-β in the treatment of COVID-19 is also briefly discussed. |
doi_str_mv | 10.1093/qjmed/hcaa348 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7928608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/qjmed/hcaa348</oup_id><sourcerecordid>2480745851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-c71755f6198ed0197a97dadb3b57e10e96b7c7f2558544a4f5d67a310b459b123</originalsourceid><addsrcrecordid>eNqFkU1vFSEUhomxsbW6dGtYuhkLAwyDCxN7_WrSpJvqljDMmXupDExh0PTfS-1t1VVXEM6T5yXnRegVJW8pUezk-mqG8WRnjWG8f4KOKO9I0zLFnt7fZSsO0fOcrwghXPL-GTpkle0EZUeonMJqsAsrpAlSDBmbjN08lxDXHSSz3NQhnotf3eIBZ-srlV1-hw0O8AvHsvoYf-AY6oP1Jmdn8ZjKFo8lubDF1YI3F9_PPjZU4cWEEWZnX6CDyfgML_fnMfr2-dPl5mtzfvHlbPPhvLFcdmtjJZVCTB1VPYyEKmmUHM04sEFIoARUN0grp1aIXnBu-CTGThpGycCFGmjLjtH7O-9ShromC2FNxusludmkGx2N0_9PgtvpbfyppWr7jvRV8GYvSPG6QF717LIF702AWLJueU8kr_G0os0dauuCcoLpIYYSfVuV_lOV3ldV-df__u2Bvu_mb3YsyyOu3y3foL8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2480745851</pqid></control><display><type>article</type><title>Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Dumitrescu, L ; Papathanasiou, A ; Coclitu, C ; Constantinescu, C S ; Popescu, B O ; Tanasescu, R</creator><creatorcontrib>Dumitrescu, L ; Papathanasiou, A ; Coclitu, C ; Constantinescu, C S ; Popescu, B O ; Tanasescu, R</creatorcontrib><description>Abstract
Beta interferons (IFN-β) are pleiotropic cytokines with antiviral properties. They play important roles in the pathogenesis of multiple sclerosis (MS), an incurable immune-mediated disorder of the central nervous system. The clinical expression of MS is heterogeneous, with relapses of neuroinflammation and with disability accrual in considerable part unrelated to the attacks. The injectable recombinant IFN-β preparations are the first approved disease-modifying treatments for MS. They have moderate efficacy in reducing the frequency of relapses, but good long-term cost-efficacy and safety profiles, so are still widely used. They have some tolerability and adherence issues, partly mitigated in recent years by the introduction of a PEGylated formulation and use of ‘smart’ autoinjector devices. Their general impact on long-term disability is modest but could be further improved by developing accurate tools for identifying the patient profile of best responders to IFN-β. Here, we present the IFN-β-based immunomodulatory therapeutic approaches in MS, highlighting their place in the current coronavirus disease (COVID-19) pandemic. The potential role of IFN-β in the treatment of COVID-19 is also briefly discussed.</description><identifier>ISSN: 1460-2725</identifier><identifier>ISSN: 1460-2393</identifier><identifier>EISSN: 1460-2393</identifier><identifier>DOI: 10.1093/qjmed/hcaa348</identifier><identifier>PMID: 33486513</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>COVID-19 Drug Treatment ; Humans ; Immunotherapy ; Interferon-beta - therapeutic use ; Multiple Sclerosis - drug therapy ; Neuroinflammatory Diseases ; Pandemics ; Review</subject><ispartof>QJM : An International Journal of Medicine, 2021-12, Vol.114 (10), p.691-697</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-c71755f6198ed0197a97dadb3b57e10e96b7c7f2558544a4f5d67a310b459b123</citedby><cites>FETCH-LOGICAL-c476t-c71755f6198ed0197a97dadb3b57e10e96b7c7f2558544a4f5d67a310b459b123</cites><orcidid>0000-0003-2282-1793</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33486513$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dumitrescu, L</creatorcontrib><creatorcontrib>Papathanasiou, A</creatorcontrib><creatorcontrib>Coclitu, C</creatorcontrib><creatorcontrib>Constantinescu, C S</creatorcontrib><creatorcontrib>Popescu, B O</creatorcontrib><creatorcontrib>Tanasescu, R</creatorcontrib><title>Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic</title><title>QJM : An International Journal of Medicine</title><addtitle>QJM</addtitle><description>Abstract
Beta interferons (IFN-β) are pleiotropic cytokines with antiviral properties. They play important roles in the pathogenesis of multiple sclerosis (MS), an incurable immune-mediated disorder of the central nervous system. The clinical expression of MS is heterogeneous, with relapses of neuroinflammation and with disability accrual in considerable part unrelated to the attacks. The injectable recombinant IFN-β preparations are the first approved disease-modifying treatments for MS. They have moderate efficacy in reducing the frequency of relapses, but good long-term cost-efficacy and safety profiles, so are still widely used. They have some tolerability and adherence issues, partly mitigated in recent years by the introduction of a PEGylated formulation and use of ‘smart’ autoinjector devices. Their general impact on long-term disability is modest but could be further improved by developing accurate tools for identifying the patient profile of best responders to IFN-β. Here, we present the IFN-β-based immunomodulatory therapeutic approaches in MS, highlighting their place in the current coronavirus disease (COVID-19) pandemic. The potential role of IFN-β in the treatment of COVID-19 is also briefly discussed.</description><subject>COVID-19 Drug Treatment</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Interferon-beta - therapeutic use</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Neuroinflammatory Diseases</subject><subject>Pandemics</subject><subject>Review</subject><issn>1460-2725</issn><issn>1460-2393</issn><issn>1460-2393</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1vFSEUhomxsbW6dGtYuhkLAwyDCxN7_WrSpJvqljDMmXupDExh0PTfS-1t1VVXEM6T5yXnRegVJW8pUezk-mqG8WRnjWG8f4KOKO9I0zLFnt7fZSsO0fOcrwghXPL-GTpkle0EZUeonMJqsAsrpAlSDBmbjN08lxDXHSSz3NQhnotf3eIBZ-srlV1-hw0O8AvHsvoYf-AY6oP1Jmdn8ZjKFo8lubDF1YI3F9_PPjZU4cWEEWZnX6CDyfgML_fnMfr2-dPl5mtzfvHlbPPhvLFcdmtjJZVCTB1VPYyEKmmUHM04sEFIoARUN0grp1aIXnBu-CTGThpGycCFGmjLjtH7O-9ShromC2FNxusludmkGx2N0_9PgtvpbfyppWr7jvRV8GYvSPG6QF717LIF702AWLJueU8kr_G0os0dauuCcoLpIYYSfVuV_lOV3ldV-df__u2Bvu_mb3YsyyOu3y3foL8</recordid><startdate>20211220</startdate><enddate>20211220</enddate><creator>Dumitrescu, L</creator><creator>Papathanasiou, A</creator><creator>Coclitu, C</creator><creator>Constantinescu, C S</creator><creator>Popescu, B O</creator><creator>Tanasescu, R</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2282-1793</orcidid></search><sort><creationdate>20211220</creationdate><title>Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic</title><author>Dumitrescu, L ; Papathanasiou, A ; Coclitu, C ; Constantinescu, C S ; Popescu, B O ; Tanasescu, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-c71755f6198ed0197a97dadb3b57e10e96b7c7f2558544a4f5d67a310b459b123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>COVID-19 Drug Treatment</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Interferon-beta - therapeutic use</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Neuroinflammatory Diseases</topic><topic>Pandemics</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dumitrescu, L</creatorcontrib><creatorcontrib>Papathanasiou, A</creatorcontrib><creatorcontrib>Coclitu, C</creatorcontrib><creatorcontrib>Constantinescu, C S</creatorcontrib><creatorcontrib>Popescu, B O</creatorcontrib><creatorcontrib>Tanasescu, R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>QJM : An International Journal of Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dumitrescu, L</au><au>Papathanasiou, A</au><au>Coclitu, C</au><au>Constantinescu, C S</au><au>Popescu, B O</au><au>Tanasescu, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic</atitle><jtitle>QJM : An International Journal of Medicine</jtitle><addtitle>QJM</addtitle><date>2021-12-20</date><risdate>2021</risdate><volume>114</volume><issue>10</issue><spage>691</spage><epage>697</epage><pages>691-697</pages><issn>1460-2725</issn><issn>1460-2393</issn><eissn>1460-2393</eissn><abstract>Abstract
Beta interferons (IFN-β) are pleiotropic cytokines with antiviral properties. They play important roles in the pathogenesis of multiple sclerosis (MS), an incurable immune-mediated disorder of the central nervous system. The clinical expression of MS is heterogeneous, with relapses of neuroinflammation and with disability accrual in considerable part unrelated to the attacks. The injectable recombinant IFN-β preparations are the first approved disease-modifying treatments for MS. They have moderate efficacy in reducing the frequency of relapses, but good long-term cost-efficacy and safety profiles, so are still widely used. They have some tolerability and adherence issues, partly mitigated in recent years by the introduction of a PEGylated formulation and use of ‘smart’ autoinjector devices. Their general impact on long-term disability is modest but could be further improved by developing accurate tools for identifying the patient profile of best responders to IFN-β. Here, we present the IFN-β-based immunomodulatory therapeutic approaches in MS, highlighting their place in the current coronavirus disease (COVID-19) pandemic. The potential role of IFN-β in the treatment of COVID-19 is also briefly discussed.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>33486513</pmid><doi>10.1093/qjmed/hcaa348</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-2282-1793</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1460-2725 |
ispartof | QJM : An International Journal of Medicine, 2021-12, Vol.114 (10), p.691-697 |
issn | 1460-2725 1460-2393 1460-2393 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7928608 |
source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | COVID-19 Drug Treatment Humans Immunotherapy Interferon-beta - therapeutic use Multiple Sclerosis - drug therapy Neuroinflammatory Diseases Pandemics Review |
title | Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T01%3A22%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beta%20interferons%20as%20immunotherapy%20in%20multiple%20sclerosis:%20a%20new%20outlook%20on%20a%20classic%20drug%20during%20the%20COVID-19%20pandemic&rft.jtitle=QJM%20:%20An%20International%20Journal%20of%20Medicine&rft.au=Dumitrescu,%20L&rft.date=2021-12-20&rft.volume=114&rft.issue=10&rft.spage=691&rft.epage=697&rft.pages=691-697&rft.issn=1460-2725&rft.eissn=1460-2393&rft_id=info:doi/10.1093/qjmed/hcaa348&rft_dat=%3Cproquest_pubme%3E2480745851%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2480745851&rft_id=info:pmid/33486513&rft_oup_id=10.1093/qjmed/hcaa348&rfr_iscdi=true |